- Novo Nordisk's Q1 in four words: Pills, pricing, payments and pressureA million patients with obesity are already taking Novo Nordisk’s Wegovy pill, CEO Mike Doustdar said Wednesday, despite the market entry of Lilly’s Foundayo. Novo's pill had sales of 2.3 billion D…Endpoints · 2mo ago↗ source
- Simlukafusp Alfa Regimens Show Manageable Safety and Activity But Do Not Outperform SOC in Metastatic RCCSimlukafusp alfa plus atezolizumab with/without bevacizumab was safe and active but did not improve upon responses with SOC treatments in metastatic RCC.onclive · 2mo ago↗ source
- Dr Cohen on Frontline Chemotherapy Selection in Metastatic Pancreatic CancerDeirdre J. Cohen, MD, MS, discusses clinical decision-making and the comparative efficacy of FOLFIRINOX and NALIRIFOX in metastatic pancreatic cancer.